Bio-Techne (TECH) has entered into a partnership with genome engineering firm Kytopen to accelerate cell therapy manufacturing, the companies said Thursday.
The collaboration will focus on combining their technologies, TcBuster GMP non-viral genome engineering system and Flowfect Tx GMP cellular engineering platform, according to a joint statement.
Shares of Bio-Techne were up more than 2% in recent trading.
Price: 49.99, Change: +1.24, Percent Change: +2.54
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。